Efectos no hipolipemiantes de las estatinas
DOI:
https://doi.org/10.51481/amc.v49i4.330Palabras clave:
Estatinas, enfermedad de alzheimer, artritis reumatoide, osteoporosis, cáncer, sepsisResumen
Las estatinas se han convertido en una de las drogas más prescritas en el mundo. Este tipo de fármacos es utilizado en el tratamiento de la dislipidemia y en la prevención de la enfermedad cardiovascular. Recientemente ha surgido nueva evidencia sobre sus mecanismos de acción y son bien conocidas sus propiedades pleiotrópicas, más allá de la disminución de los niveles de colesterol. Esta característica farmacodinámica ha llamado la atención de muchos investigadores quienes sugieren su uso en diferentes enfermedades que se centran en la inflamación, en desórdenes de la inmunidad y en la proliferación celular. Aunque hay amplia evidencia que reconoce su eficacia en diversos modelos de enfermedades, todavía existe una falta de estudios que apoyen su uso en la práctica clínica. En este trabajo se revisa el mecanismo de acción de estos fármacos y de la base fisiopatológica que sugiere su uso clínico en diferentes enfermedades
Descargas
Citas
Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992; 33: 1569-1582.
West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland prevention study. Circulation. 1998; 97: 1440-1445.
Plehn J, Davis B, Sacks F, Rouleau J, Pfeffer M, Bernstein V. Reduction of stroke incidence after myocardial infartion with pravastatin: The cholesterol and recurrent events (CARE) study. Circulation. 1999; 99: 216-223.
Heart Protection Study Collaborative Group. MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high – risk individuals: a randomized placebo – controlled trial. Lancet. 2002; 360: 7-22.
Schwartz G, Olsson A, Ezekowitz M, Ganz P, Olivier M, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 2001; 285: 1711-1718.
Waters D, Schwartz G, Olsson A, Zeiher A, Olivier M, Ganz P, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-q-wave myocardial infarction. Circulation. 2002; 106: 16901695.
Kannel W.B., Castelli W.P., Gordon T, McNamara P.M. Cholesterol lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1971; 74: 1-12.
Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 1982; 248: 1465-1477.
Sever P.S. Lipid – lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo – Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Med. 2005; 118:3S-9S.
The Stroke Prevention by Agressive Reduction in Cholesterol Levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-559.
Iso H, Jacobs D.R., Wentworth D, Neaton J.D., Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320: 904-910.
Amarenco P, Tonkin A.M., Statin for stroke prevention. Dissapointment and hope. Circulation. 2004; 109: III44-III49.
Bang O.Y., Saber J.L., Liebeskind D.S., Starkman S, Villablanca P, Salamon N, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke. Neurology. 2007; 68: 737-742
Pedersen T.R, Faegeman O, Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005; 294: 2437:2445.
Wiviott S.D., Cannon C.P., Morrow D.A., Ray K.K., Pfeffer M.A., Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol. 2005; 46: 1411-1416.
White H.D., Simes R.J., Anderson N.E., Hankey G.J., Watson J.D., Hunt D., et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000; 343: 317-326.
Nissen S.E., Nicholls S.J., Sipahi I, Libby P, Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA. 2006; 295:1556-1565.
Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk of brain infarction. Neurology. 2001; 57: S35-S44.
Iribarren C, Jacobs D.R., Sadler M, Claxton A.J., Stephen S. Low total cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? Stroke. 1996; 27:1993-1998.
Woo D, Kissela B.M., Khoury J.C., Sauerbeck R.N., Haverbusch M.A., Szaflarski J.P., et al. Hypercholesterolemia, HMG-coA reductase inhibitors, and risk of intracerebral hemorrhage. Stroke. 2004; 35: 1360-1364.
Sever P, Dahlof B, Poulter N. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who average or lower than average cholesterol concentrations, in the Anglo – Scandinavian Cardiac Outcomes Trial – Lipid Lowerin Arm (ASCOT–LLA). Lancet. 2003; 361:1149-1158.
Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002; 110: 285-288.
van Aelst L, D`Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997; 11: 2295-2322.
Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui D, Yang S, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000; 1: 15-24.
Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz M, et al. Stroke protection by 3-hidroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci. 1998; 95: 8880-8885.
Zhang H, Schmeiber A, Garlichs C, Plötze K, Damme U, Mügge A, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/ NADPH-oxidases. Cardiovasc Res. 1999; 44: 215-222.
Wassmann S, Laufs U, Bäumer A, Müller K, Konkol C, Sauer H et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001; 59: 646-654.
Pliquett R, Cornisa C, Zucker I. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol. 2003; 95: 700-704.
Mozzafarian D, Nye R, Levy R. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004; 93: 1124-1129.
Wolrom S, Jensen K, Liao J. Endothelium – dependent effects of statins. Arterioescler Thromb Vasc Biol. 2003; 23: 729-736.
O’Driscoll G, Green D, Taylor R.R. Simvastatin, an HMG-coenzyme: a reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126–1131.
Strey C.H., Young J.M., Lainchbury J.H., Frampton C.M., Nicholls MG, Richards AM et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure.
Heart. 2006; 92: 1603-1609.
Degraeve F, Bolla M, Blaie S, Créminon C, Quére I, Boquet P, et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. J Biol Chem. 2001; 276: 46849-46855.
Hernández O, Pérez D, Navarro J, Sánchez R, Hernández G, Díaz C et al. Effects of the 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998; 12: 2711-2719.
Kimura M, Kurose I, Russell J, Granger D. Effects of fluvastatin on leukocyte–endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997; 17: 1521-1526.
Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathway lead to the activation of the nuclear factor kappa B by the Rho family of GTPases. J Biol Chem. 1998; 273:12779-12785.
Gauthier T, Scalia R, Murohara T, Guo J, Lefer A. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercolesterolemia. Arterioscler Thromb Vasc Biol. 1995; 15: 16521659.
Pruefer D, Scalia R, Lefer A. Simvastatin inhibits leukocyte– endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999; 19: 2894-2900.
Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001; 7: 687692.
Ridker P, Rifai N, Clearfield M, Downs J, Weis S, Miles S, et al. Measurements of C-Reactive Protein for the targeting statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344: 1959-1965.
Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107: 363-369.
Mora S, Ridker P. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatina (JUPITER) Can C-Reactive protein be used to target statin therapy in primary prevention. Am J Cardiol. 2006; 97: 33-41.
Youseff S, Stüve O, Patarroyo J, Ruiz P, Radosevich J, Mi Hur E, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes aTH2 bias and reverse paralysis in central nervous system. Nature. 2002; 420: 78-74.
Dunn A, Youssef S, Goldstein M, Prod`homme T, Weber M, Zambill S, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006; 203: 401-412.
Kobashigawa J, Katznelson S, Laks H, Johnson J, Yeatman L, Ming Wang X, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333: 621-627.
Kwak B, Mulhaupt F, Myit S, Mach F. Statins as newly recognized type of immunomodulator. Nat Med. 2000; 6: 1399-1402.
Hindler K, Cleeland C, Rivera E, Collard C. The role of statins in cancer. Oncologist. 2006; 11: 306-315.
Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001; 22: 1139-1148.
Dimitroulakos J, Ye L, Benzaquen M, Moore M, Kamel-Reid S, Freedman M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin – induced apoptosis:
therapeutic implications. Clin Cancer Res. 2001; 7: 158-167.
Agarwal B, Bhendwal S, Halmos B, Moss S, Ramey W, Holt P. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer. Clin Cancer Res. 1999; 5: 2223-2229.
Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005; 26: 883-891.
Mo H, Elson C. Studies of the isoprenoid – mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med. 2004; 229: 567-585.
Weis M, Heeschen C, Glassford A, Cooke J. Statins have biphasic effects on angiogenesis. Circulation. 2002; 105: 739-745.
Blennow K, de Leon M, Zetterberg H. Alzheimer disease. Lancet. 2006; 368: 387-403.
Bodovitz S, Klein W, Cholesterol modulates secretase cleavage of amyloid precursor protein. J Biol Chem. 1996; 271: 4436-4440.
Howland D, Trusko S, Savage M, Reaume A, Lang D, Hirsch J, et al. Modulation of secreted beta – amyloid precursor protein and amyloid beta peptide in brain by cholesterol. J Biol Chem. 1998; 273: 657616582.
Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function of the LDL receptor: Transcytosis of LDL across the blood brain barrier. J Cell Biol. 1997; 138: 877-889.
Butterfield A, Perluigi M, Sultana R. Oxidative stress in Alzheimer`s disease brain: new insights from redox proteomics. Eur J Pharmacol. 2006; 545: 39-50.
DeKoski ST. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am J Med. 2005; 118: 48S-53S.
Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanisms of statins – mediated inhibition of small G-protein funtcion. J Biol Chem. 2005; 280: 34202-34209.
Cordle A, Landreth G. 3-Hydroxy-3-Methylglutaryl CoA reductase inhibitors attenuate beta amyloid – induced microglial inflammatory responses. J Neurosci. 2005; 25: 299-307.
Bi X, Baudry M, Liu J, Yao Y, Fu L, Brucher F et al. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3methylglutaryl (HMG)-CoA reducatse inhibitors on microglia. J Biol Chem. 2004; 279: 48238-48245.
Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer`s Disease. J Neurol Neurosurg Psychiatry. 2005; 76: 1624-1629.
Wolozin B, Kellman W, Rousseau P, Celesia G, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-Hydroxy-3Methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57: 1439-1443.
Jick H, Zornberg G.L., Jick S.S., Seshadri S, Drachman D.A. Statins and the risk of dementia. Lancet. 2000; 356: 1627-1631.
Zandi P, Sparks L, Khachaturian A, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce the risk of incident dementia and Alzheimer`s disease. Arch Gen Psychiatry. 2005; 62: 217-224.
Li G, Higdon R, Kukull W, Peskind E, Van Valen K, Tsuang D et al. Statin therapy and risk of dementia in the elderly. Neurology. 2004; 63: 1624-1628.
Rea T.D., Breitner J.C., Pstay B.M., Fitzpatrick A.L. Lopez O.L., Newman A.B., Statin use and the risk of incident dementia. Arch Neurol. 2005; 62: 1047-1051.
Padala K, Padala P, Potter J. Simvastatin – induced decline in cognition. Ann Phamacother. 2006; 40: 1880-1883.
Demer L. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int J Epidemiol. 2002; 31: 737-741.
Hamaerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM. 2005; 98: 467484.
Das U. Nitric oxide as the mediator of the antiosteoporotic actions of estrogen, statins, and essential fatty acids. Exp Biol Med. 2002; 227: 88-93.
Doherty T, Asotra K, Fitzpatrick L, Qiao J.H., Wilkin D, Detrana R, et al. Calcification in atherosclerosis and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci. 2003; 110:11201-11206.
Parhami F, Garfinkel A, Demer L. Role of lipids in osteoporosis. Arterioscl Thromb Vasc Biol. 2000; 20: 2346-2348.
Majima T, Komatsu Y, Fukao A, Ninomiya K, Matsumara T, Nakao K. Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J. 2007; 54: 145-151.
Garrett I, Mundy G. The role of statins as potential targets for bone formation. Arthritis Res. 2002; 4: 237-240.
Fisher J.E., Rogers M.J. Halasy J.M., Luckman S.P., Hughes D.E. Masarachia P.J., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci. 1999; 96: 133–138.
Samelson E, Kiel D, Broe K, Zhang Y, Cupples LA, Hannan M, et al. Metacarpal cortical area and risk of coronary heart disease. The Framingham Study. Am J Epidemiol. 2004; 159: 589-595.
Poli A, Bruschi F, Cesana B, Rossi M, Paoletti R, Crosignani PG. Plama low density lipoprotein cholesterol and bone mass in postmenopausal women. Obstet Gynecol. 2003; 102: 922-926.
Chan A, Andrade S, Boles M, Buist D, Chase G, Donahue J, et al. Inhibitors of hydroxymethylglutaryl-coenzime A reductase and risk of fracture among older women. Lancet. 2000; 355: 2185-2188.
Meier C, Schlienger R, Kraenzlin M, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000; 283: 32053210.
Pasco J, Kutowicz M, Kerry S, Nicholson G, et al. Statin use, bone mineral density, and fracture risk. Geelong Osteoporosis Study. Arch Intern Med. 2002; 162: 537-540.
Wang P, Solomon D, Mogun H, Avorn J. HMG – CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000; 283: 3211-3216.
Scranton R, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk. Study of an US Veterans Population. Arch Intern Med. 2005; 165: 2007-2012.
Bauer D, Mundy G, Jamal S, Black D, Cauley J, Ensrud K. Use of statins and fracture. Results of 4 prospective studies and cummulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004; 164: 146-152.
LaCroix A, Cauley J, Pettinger M, Hsia J, Bauer D, McGowan J, et al. Statin use, clinical fracture, and bone density in postmenopausal women: Results from the Women Health Initiative Observational Study. Ann Intern Med. 2003; 139: 97-104.
McInnes I, McCarey D, Sattar N. Do Statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis. 2004; 63: 1535-1537.
Pasceri V, Yeh E. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100: 2124-2126.
McCarey D, McInnes I, Madhock R, Hampson R, Scherbakova O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA) double – blind, randomised, placebo controlled trial. Lancet. 2004; 363: 2015-2021.
Leung B, Saltar N, Crilly A, Prach M, McCarey D, Pyne H, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003; 170: 1524-1530.
Kinderlerer A, Steinberg R, Johns M, Harten S.K., Lidington E.A., Haskard D.O., et al. Statin – induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the antiinflammatory actions of statins in rheumatoid arthritis. Arthritis Res Ther. 2006; 8: R130.
Hermann F, Forster A, Chenevard R, Enseleit F, Hürlimann D, Corti R. Simvastatin improves endothelial in patients with rheumatoid arthritis. J Am Coll Cardiol. 2005; 45: 461-464.
Solomon D, Karlson E, Rimm E, Cannuscio C, Mandl L, Manson J, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107: 1303-1307.
Doornum S, McColl G, Wicks I. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004; 63: 15711574.
Arnett D, Evans G, Riley W. Arterial stiffness: A new cardiovascular risk factor. Am J Epidemiol. 1994; 140: 669-682.
Graaf M, Baiderbeck A, Egberts A, Richel D, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004; 22: 2388-2394.
Bonovas S, Filioussi K, Tsavaris N, Sitaras N. Statin and cancer Risk: A literature-based meta-analysis and meta-regression. Analysis of 35 randomized controlled trials. J Clin Oncol. 2006; 24: 4808-4817.
Poynter J, Gruber S, Higgings P, Almog R, Bonner J, Rennert H, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352: 2184-2192.
Shannon J, Tewoderos S, Garzotto M, Beer T, Derenick R, Palma A, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol. 2005; 162: 318-325.
Platz E, Leitzmann M, Visvanathan K, Rimm EB, Stampfer M.J., Willet W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006; 98: 1819-1825.
Cauley J.A., McTiernan A, Rodabough R.J., La Croix A, Bauer D.C., Margolis K.L., et al. Statin use and breast cancer: prospective results from the women`s health initiative. J Natl Cancer Inst. 2006; 98: 700707.
Dimitroulakos J, Nohynek D, Backway K, Hedley D, Yeger H, Freedman H, et al. Increased sensitivity of acute myeloid leukemias to lovastatin induced apoptosis: a potential therapeutic approach. Blood. 1999; 93: 1308-1318.
Setoguchi S, Glynn R, Avorn J, Schneeweiss S. Statins and the risk of lung, breast and colorectal cancer in the elderly. Circulation. 2007; 115: 27-33.
Elliasen A.H., Colditz G, Rosner B, Willett W, Hankinson S. Serum lipids, lipid – lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005; 165: 2264-2271.
Bonovas S, Filioussi K, Tsavaris N, Sitaras N. Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005; 23: 8606-8612.
Moorman P, Hamilton R. Statins and cancer risk: What do we know and where do we go from here. Epidemiology. 2007; 18: 194-196.
Mo H, Elson C. Studies of the isoprenoid – mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med. 2004; 229: 567-585.
Almog Y. Statins, inflammation and sepsis. Hypothesis. Chest. 2003; 124: 740–743.
Merx M.C., Liehn E.A., Graf J, van de Sandt A, Schaltenbrand M, Schrader J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation. 2005; 112: 117-124.
Miessner A, Steiner S, Speidl W.S., Pleiner J, Seidinger D, Maurer G, et al. Simvastatin suppresses endotoxin-induced upregulation of tolllike receptors 4 and 2 in vivo. Atherosclerosis. 2006; 189: 408–413.
Gupta R, Plantinga L.C., Fink N.E., Relamed M.L., Coresh J, Fox C.S., et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA. 2007; 297: 1455-1464.
Hackam DG, Mamdani M, Li P, Redelmeir DA. Statins and sepsis in patients with cardiovascular disease: a population – based cohort analysis. Lancet. 2006; 367: 413–418.
Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004; 110: 880–885.
Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 2006; 32: 75–79.
Novack V, Terblanche M, Almong Y. Do statins have a role in preventing or treating sepsis? Crit Care. 2006; 10: 113-115.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2008 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
